Biolargo Stock Price, News & Analysis

BioLargo, Inc. (OTCQB:BLGO) has launched a new PFAS Testing Program to help customers identify PFAS contamination in their water. This program addresses the growing regulatory challenges regarding PFAS, a group of harmful chemicals found in drinking water. The testing provides accurate results, enabling the company to recommend appropriate treatment solutions. BioLargo's Aqueous Electrostatic Concentrator (AEC) offers a sustainable method for PFAS removal, generating significantly less waste than conventional methods. This initiative aims to support municipalities facing PFAS-related water well closures.

BioLargo, Inc. (OTCQB:BLGO) will participate in Water Solutions 6 on August 26, 2021, from 1:30 pm to 5:00 pm PT. This virtual conference focuses on water conservation and innovations. Tonya Chandler, BioLargo's Director of Strategic Marketing, will present its technology for removing PFAS contaminants from water. As a title sponsor, BioLargo encourages public registration with the promo code WS6BLGOCOMP. The event features notable speakers, including state water officials and industry leaders.

BioLargo (OTCQB:BLGO) announced key developments in its Quarterly Report on August 17, 2021, highlighting an 11% increase in consolidated revenue to $464,000 for Q2 2021. The company has made strides in commercializing PFAS treatment technology and reducing its debt by over $4 million since 2019. New contracts worth $1.2 million are expected to boost cash flow. A peer-reviewed paper validates the safety of its water treatment technology, supporting its market position. The company is actively pursuing further significant revenue opportunities.

Summary not available.

BioLargo, Inc. (OTCQB:BLGO) will host a webcast on August 17, 2021, at 8:00 am PST / 11:00 am EST, to discuss its financial results and recent events. The public is invited to participate. Replay of the webcast and teleconference will be available for a limited time on their Investor Relations webpage. BioLargo focuses on innovative technologies addressing environmental issues, such as PFAS contamination and water treatment, supported by over 80 awarded grants and numerous pilot projects. For more details, visit BioLargo's website.

BioLargo, Inc. (OTCQB:BLGO) will present at the SNN Network Summer Virtual Event 2021 on August 18 at 10 AM ET. CEO Dennis P. Calvert will discuss BioLargo's sustainable environmental technologies and engage with investors. The presentation focuses on solutions for water contamination, PFAS remediation, and air quality control. Attendees can access the presentation via a provided link. If unable to attend live, recordings will be available on the event's platform. Interested investors can also schedule one-on-one meetings with the company.

BioLargo (OTCQB:BLGO) is advancing its PFAS treatment technology, beginning tests with water samples from potential clients, including a major municipality and a federal agency in Southern California. This initial phase aims to demonstrate the effectiveness of its Aqueous Electrostatic Concentrator (AEC) system in removing PFAS contaminants. Success here could lead to larger-scale pilot programs. The recent PFAS Action Act of 2021 may enhance demand for such solutions, positioning BioLargo favorably as it boasts over 99% PFAS removal efficiency, generating significantly less waste than traditional methods.

BioLargo, Inc. (OTCQB:BLGO) announced new contract awards totaling over $1.2 million, anticipated to enhance operating cash flow and support revenue growth. The contracts involve projects with a resin manufacturing facility, a dairy farm, and a US Air Force base, among others, with most revenue expected in the next six months. CEO Dennis P. Calvert expressed optimism about the growth trajectory of their engineering subsidiary, emphasizing the potential for commercialization of patented environmental technologies.

BioLargo (OTCQB:BLGO) has announced a peer-reviewed study affirming that its Advanced Oxidation System (AOS) generates fewer disinfection by-products than conventional wastewater treatment methods. Conducted by the University of Calgary, the research indicates that AOS's by-product levels are similar to those in ordinary tap water. The technology not only enhances disinfection but also minimizes electricity consumption and effectively removes pharmaceutical micropollutants. This advancement paves the way for its commercialization in municipal wastewater treatment applications.